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Abstract
Our research is focused on the production of a hemoglobin based oxygen carrier (HBOC)
which can be used as a therapeutic in the event of acute blood loss. The administration of
cell-free hemoglobin is associated with severe adverse effects due to dissociation of the
tetrameric α₂β₂ complex into αβ heterodimers. Our approach to the design of an effective
HBOC, is based on a recombinant circularly permuted human hemoglobin in which all of the
subunits are linked in a single-chain fashion. This design would prevent the dissociation of
the tetramer and allow for the biosynthesis of polymeric hemoglobins of defined mass.
Preliminary ligand binding data with our permuted hemoglobins indicate that they prefer the
high O₂-affinity R-state conformation over the low O₂-affinity T state. The βN108K and
αV96W mutations were introduced to restore T state stability. Preliminary studies of the
mutants have shown that while the βN108K mutation improved T-state stability, the αV96W
mutation, in the context of the permuted hemoglobin backbone, displays an unexpected
destabilizing effect on the T state. We have inserted the βN108K mutation into our single
chain hemoglobin in order to obtain structural and functional data however it was discovered
that this change significantly decreases expression yield. We would like to utilize X-ray
crystallography to gain an atomic-level picture of protein structural differences that could
explain the results from our αV96W mutants. Crystallization trials are underway for the
αV96W mutant as well as the βN108K mutant and a αV96W + βN108K double mutant. To
date no crystals have been obtained that diffract X-rays.
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Introduction
Need for a red blood cell substitute. In current medical practice, red blood cell
transfusions are the accepted course of treatment in cases of acute blood loss. The need for
donated blood to supply red cells for transfusion is constant, given the 42-day shelf life for
donated red cells. The emergence of AIDS in the 1980s spurred research efforts to find a red
blood cell alternative. In the United States of America, strict screening and testing has
reduced this risk considerably so that the occurrences of HIV/AIDS from blood transfusion is
1 in 2 million, Hepatitis B is 1 in 78,000 and Hepatitis C is 1 in 827,000.1 This screening
contributes to not only raising the cost of blood, but also reducing eligible donors which is a
considerable concern in developing nations.2 In addition to this, it is difficult to anticipate
emerging blood-borne infectious diseases.3 Transmissible diseases are not the only concerns
with blood transfusion. Some of the other complications include transfusion related acute
lung injury or TRALI (1 in 5000), immunosuppression and risk of blood type mismatch.4-6
Ensuring that the blood supply is sufficient to meet the projected demand for
transfusions has also been a growing concern. The blood supply is limited by several factors
such as the shelf life of red blood cells and eligible donors. Figure 1 shows the 2011 national
blood collection and utilization survey for blood transfusions in the United States.7 The
report indicated a 14.8% reduction in blood donations suitable for transfusion compared to
the 2008 survey. The key concern is the shrinking margin between available collections
(supply) and transfusions (demand) which in 2011 was at 5.2%.7 In addition to this, the mean
donor age is increasing meaning that as the population ages the donor pool will be decreasing

leading to a shortage of blood unless the recruitment and retention of donors who are young
adults and middle aged is improved.8 Furthermore it is believed that the doubling of U.S.
population over the age of 65 will result in an increase in the demand for blood transfusion. 6
Another difficulty with supply and demand is that in the wake of a disaster red blood cells
will be in high demand with low supply.2

Figure 1: Blood Collection and Transfusions in the US from 1989 to 2011. The figure compares total
collections (diamonds), available collections (excludes rejected supplies- triangles) and transfusions
(circles) 7

The shelf lives of whole blood and packed red cells are, respectively, 28 and 42 days.
The fact that whole blood and red cells cannot be stored indefinitely drives the need for
constant blood donation and the interest in developing a blood substitute. Recent studies
show that the quality of stored blood decreases rapidly after its collection. For example,
2

Figure 2 shows that the efficiency of oxygen delivery of blood stored for more than a week is
considerably decreased.9 The 14 day old blood has a higher affinity for oxygen binding as
seen by the higher percent of oxygen saturation at a lower oxygen concentration when
compared to freshly collected blood. The result of this is that old blood will release only 5%
of the oxygen content compared to the 25% of oxygen content released by fresh blood. This
effect is most likely due to the depletion of 2,3 bisphosphoglycerate (2,3 BPG, which is a
regulator of hemoglobin oxygen affinity). Another concern is the mounting evidence of red
blood cell lesions which include the time-dependent metabolic, biochemical, and molecular
changes of stored red blood cells resulting in cellular injury in vitro. These lesions are linked
to acute adverse effects after transfusion with old but not outdated blood.10, 11 Another study
found that even after just three hours post collection the S-nitrosohemoglobin (SNO-Hb)
levels, which play a role in RBC-dependent vasoregulatory function, were reduced. This
reduction is a concern as it suggests that even “fresh” blood may increase adverse biological
effects such as vasoconstriction.12

3

Figure 2: Oxygen affinity curve of fresh blood and blood stored for 14 days as a function of oxygen
concentration9

Blood-borne pathogens, shelf life, cost of testing for safety, and limitations due to
required cross matching are major concerns with blood transfusion using donated blood. To
address these concerns, research efforts have been focused on developing a red blood cell
(RBC) substitute with the following characteristics: (1) long shelf life (up to a year), (2) no
risk to the patient in terms of side effects and blood-borne pathogens, and (3) cost-effective
to produce on a large scale.13
Hemoglobin: One of the main roles of RBCs is the delivery of oxygen to the tissues,
and this is the feature of RBCs that so called “blood substitutes” attempt to mimic. RBCs are
an efficient oxygen delivery system due to the high concentrations of hemoglobin protein
within the cell. Hemoglobin (Hb) is a α₂β₂ tetramer that functions as a symmetric dimer of αβ
4

heterodimers (Figure 314). Each subunit contains a heme prosthetic group which is the site of
reversible oxygen binding. Hemoglobin has two main conformational states. The relaxed
conformational state (R state) has a high affinity for oxygen binding and is favored in
locations with high oxygen concentration such as the lungs. The tense conformational state
(T state) has a lower oxygen binding affinity and is found in locations of low oxygen
concentration such as the peripheral tissues.

Figure 3: Hemoglobin structure in the R (oxy) state and the T (deoxy) state 14

Current approaches to RBC substitutes. Oxygen delivery therapeutics can be divided
into two categories: allogeneic red blood cells and acellular oxygen carriers. Allogeneic red
blood cells refers to the donated blood, although there is a developing field of research where
stem cells are used to produce red blood cells for transfusion.15, 16 Acellular oxygen carriers
are oxygen delivering molecules that function outside the red blood cell and consist of two
main types. Synthetic molecules, which mostly consist of fluorinated organic fluids or
perfluorocarbons (PFCs). Several examples of PFCs are shown in Figure 4.9 These molecules
are well known for their increased ability to dissolve oxygen compared to aqueous solutions,
5

and their chemical and biological inertness. Thus, they have been considered as an alternative
to RBCs. The major drawback to using PFCs is that the patient needs to be in an oxygenenriched atmosphere in order to achieve saturation of the PFC solutions with sufficient
oxygen to supply peripheral tissues.9

Figure 4: Examples of some PFCs 9

The second type of acellular oxygen carriers use hemoglobin to carry the oxygen and
are known as hemoglobin-based oxygen carriers (HBOCs). Cell free hemoglobin is
considered to be the first HBOC, however, it was shown to have adverse side effects such as
nephrotoxicity17, toxicity associated with oxidation of the heme groups, and systemic
vasoconstriction.18, 19
Adverse effects of cell free hemoglobin: The major toxic side effect is
nephrotoxicity17. Studies have shown that cell free hemoglobin favors the dissociation of the
α2β2 tetramer into αβ heterodimers which are small enough to be filtered by the kidney
causing irreversible renal tissue damage.18, 19 This side effect has been countered by
6

introduction of covalent crosslinks between hemoglobin subunits, which physically prevent
dissociation of the tetramer into αβ heterodimers.20, 21
The second toxic side effect is caused by the oxidation of the heme groups to produce
methemoglobin. Methemoglobin does not bind oxygen resulting in anemia. Methemoglobin
has reduced heme-binding affinity, which results in the deposition of toxic Fe3+ heme in
tissues. The mechanism of methemoglobin formation also produces superoxides22 which can
cause tissue damage. The current work involving HBOCs is focused on minimizing these
effects while maintaining efficient oxygen delivery.
Another significant adverse effect of cell-free hemoglobin administration is
vasoconstriction.18 The primary cause of vasoconstriction is considered to be the scavenging
of NO by oxyhemoglobin. Recent studies have shown that vasoconstriction is not dependent
on NO binding affinity to hemoglobin, 23, 24 but the rate of NO scavenging.25 Several
preclinical studies have shown that increased size of HBOCs are correlated with decreased
vasoconstriction.26-29 The results of one such study can be seen in Figure 5.26 The prevailing
theory is that outside of the red blood cell the oxyhemoglobin molecules are small enough to
escape from the blood vessels into the intracellular space where they then oxidize nitric oxide
to nitrate ion. The nitric oxide is a smooth muscle relaxation factor; thus, the oxidation (or
“scavenging”) of NO by the hemoglobin results in vasoconstriction.

7

Figure 5: The effect of hemoglobin size on the mean arterial pressure (MAP) which is an indicator of
vasoconstriction as a function of time. The purple squares represent the control (a solution of buffered
human serum albumin), the orange triangles represent a recombinant tetramer, the blue circles a linked
dihemoglobin (two tetramers) and the green crosses a tetrahemoglobin molecule (4 tetramers). 26

Hb modification types. To date there have been three main approaches to the design
of an HBOC that minimize these toxic side effects. The first is the generation of polymerized
hemoglobin solutions where several hemoglobin molecules are linked via a chemical
crosslinker such as o-raffinose as found in Hemolink30, an HBOC whose Phase II trials were
suspended in 2004.31 These hemoglobin molecules are much larger and exhibit reduced
tetramer dissociation and vasoconstriction; however, they have a lowered oxygen affinity
compared to whole blood cell (see Figure 732). Hemopure and PolyHeme are HBOCs
generated by polymerization of hemoglobin with glutaraldehyde.30 Both made it through
phase III trials, but subsequent to that were not approved by the FDA for use in humans.31

8

Figure 6: Simplified representation of the main modifications of hemoglobin that are used in creating
HBOCs. Polymerized Hb involves the linking of multiple Hb molecules via chemical modification,
crosslinked Hb involves the linking of the globin subunits via either a chemical crosslinker or genetic
modification. Conjugated Hb involves using molecules such as polyethylene glycol (PEG) to modify
the surface of the Hb molecules.

The second approach involves crosslinking of the subunits to prevent dissociation,
either chemically or via genetic modification. Generally the two alpha subunits or the two
beta subunits are crosslinked. These modifications avoid the side effects associated with
heterodimer dissociation and have the most similar oxygen affinity compared to human red
blood cells (see Figure 732) but do not adequately address vasoconstriction.

9

Figure 7: Comparison of oxygen dissociation curves of human hemoglobin and several RBC
substitutes. The representatives are PEG-Hb, Human RBCs, αα-crosslinked Hb, o-raffinose
polymerized Hb and perfluorocarbon emulsions.32

The third approach is to generate a chemically-modified hemoglobin where the
surface of the hemoglobin molecule is conjugated with polyethylene glycol (PEG). The
conjugation increases the hydrodynamic radius of the hemoglobin resulting in reduced
vasoconstriction; however, the conjugated molecules have a higher ligand binding affinity
which means that the delivery of oxygen is not as efficient compared to whole blood (see
Figure 732). Hemospan and PEG-Hb are examples of HBOCs that have been modified using
PEG-conjugation.30 PEG-Hb trials were suspended after Phase Ib trials in 1997 while
10

Hemospan has undergone Phase III trials in Europe.31 Another approach has been to
encapsulate hemoglobin products in a phospholipid membrane thus mimicking the effect of
the red blood cell to some degree (see Figure 8). However, it is difficult to produce uniform
particle sizes and the impact to the reticular endothelial system (which consist of cells that
are phagocytic and involved in the clearance of foreign substances and worn-out or abnormal
body cells33) upon clearance is not well documented.32 Other emerging approaches include
creating hemoglobin micro particles to prevent subunit dissociation and increase retention in
the vasculature.34

Figure 8: Diagram of some types phospholipid membranes used to encapsulate Hb molecules9. Where
a represents a plain phospholipid bilayer membrane, b represents a polymerized lipid membrane, c
represents a PEG decorated membrane and d is represents an allosteric effector, enzyme, antioxidant
and cryoprotector supplementation.

Hb sources. There are three main sources of hemoglobin used in HBOC research. The
first is human hemoglobin extracted from outdated donated blood. The concerns associated
with this source include the limited supply and the risk of blood-borne pathogens.9,32 The
11

second source is from bovine red blood cells. This is a plentiful source but has a chance to be
contaminated by pathogens. To avoid this would require raising dedicated, controlled herds
of cows and harvesting blood in accordance to good manufacturing practices which is not the
current norm for bovine blood.9 The third source is recombinantly produced hemoglobin. The
hemoglobin gene can be expressed in bacterial cell such as Escherichia coli (E.coli). The β
globin was first produced in E.coli by Nagai et al. in 1985.35 The entire hemoglobin gene was
expressed in 1990 by Hoffman et al.36 This method is advantageous as it allows for site
specific modifications via site directed mutagenesis rather than general non-specific chemical
modifications. In addition, it is in theory a plentiful source of material and free of human
pathogens. The drawback to using recombinant hemoglobin is that it must be purified to a
high degree to avoid contamination of lipopolysaccharides (LPS) which increases production
costs.37
Single chain hemoglobin approach. Our approach to producing a safe and effective
HBOC is to use recombinant technology to link the subunits in hemoglobin in a single-chain
fashion, creating an internally crosslinked protein monomer unit, which can act as the
building block for a polymeric hemoglobin molecule of defined size (see Figure 9). The
intramonomer linkages prevent the dissociation of the subunits while the intermonomer
linkages yield a larger molecular weight hemoglobin with reduced vasoactivity.
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Figure 9:Template for using single chain Hb to produce a polyhemoglobin molecule of defined size
using intramonomer linkages (purple and black) and intermonomer linkages (green).

The first step in this approach is to determine sites for the intra-monomer linkers
between monomer subunits. Linkage at the existing N- and C- termini is simplest, and ought
to be considered first. In the case of the α globins this is practical as the termini are separated
by 2 Å (see Figure 10). In fact, this covalent connection between α globins has been reported
previously by Looker et al.38 The linkage of the α and β globins is more problematic as the
termini in these cases are 50 Å apart (see Figure 10). Long peptide linkers are less desirable
than shorter ones for maintaining protein stability and proper folding. 39 Because the linker
between the two α globins has been shown to yield functional hemoglobin38, relocation of the
termini in the β globin was considered to allow shorter linkers between the α and β subunits.
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Figure 10: On the left is the distance between the termini of the two α globins in a hemoglobin
molecule while on the right is the distance between the termini of the α and β globins. 35

The relocation of the β globin termini should position the new termini in close
proximity to the α globin. At the interface between the α and β globins there are 2 loops
between the G and H helices (each subunit has 8 helices which surround the heme group
designated A through H from the N- to C- terminus, see Figure 1140). These loops are as
close as any two loops in the hemoglobin structure (see Figure 12). Relocation of the β
termini to this new position allows for short linkers (5 amino acids or fewer) between the α
and β globins. The β globin termini were relocated to the G-H loop utilizing circular
permutation (see Figure 13) which had been previously shown to be tolerated in the
homologous globin protein myoglobin.41 The two native termini of the β globin were linked
with an 8-amino acid sequence, and new termini were created in the G-H loop as shown
schematically in Figure 13. The mutant containing the circularly permuted (cp) β globin
associated with a wild-type α is called “α-cpβ”.

14

Figure 11: Labeling of helices in a hemoglobin subunit40.

Figure 12: The G and H loops at the αβ interface are separated by roughly 10 Å, and therefore are
good candidates for the placement of the new β termini which will be covalently bound to the α
globin.
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Figure 13: A diagram of the circular permutation process where the first step is to add a linker
between the native N- and C- termini and then create a new termini by cleavage at the desired new
location

The next step was the linkage of the α and the circularly permuted β globins resulting
in single-chain α-cpβ (sc-α-cpβ). The final step was to link two sc-α-cpβ globins to create the
single chain hemoglobin (scHb). The progression of steps that create these novel intersubunit
linkages is shown in Figure 14.

16

Figure 14: Schematic of the progression from wild-type hemoglobin to scHb. Step one is circular
permutation of the β globin. Step 2 is covalent linkage between the cpβ globin and α globin. Step 3
is covalent linkage between the α globins in two sc-α-cpβ proteins.

T state destabilization. Initial ligand binding studies of the α-cpβ mutant were
performed using laser flash photolysis. In full flash photolysis fully liganded hemoglobin is
irradiated by a large pulse from a laser, which photolyzes the bound ligand and yields a
mixture of partially liganded and unliganded hemoglobins (see Figure 15). The rate at which
the ligand rebinds the hemoglobin is measured and allows for the determination of fast and
slow ligand binding rates, which arise from ligand binding to the R and T sates respectively.
In partial photolysis experiments an average of less than one ligand per hemoglobin is
removed via photolysis, resulting in a population of hemoglobin molecules primarily in the R
state conformation (see Figure 16). Because this experiment generates hemoglobins in the R
state, we expect a monophasic rate. The results of these studies showed that while our
mutants have a similar fast phase (representing the binding of ligands to the R state) the
amplitude of the slow phase shows that the T state is present at significantly lower
concentrations when compared to wild type hemoglobin (see Figure 17). This observation
suggests that the T state has been destabilized in the mutant.42
17

Figure 15: Full Photolysis generates a mixture of R and T state molecules, which rebind ligand at
different rates.

Figure 16: Partial Photolysis generates R state molecules which display rapid ligand rebinding rates.

18

Figure 17: Flash Photolysis of αcpβ and HbA. Panel A shows the full flash photolysis experiment
in which both the T and R state rebinding of ligands are measured. Panel B shows the partial flash
photolysis experiment in which the fast rate for rebinding of ligands to the R state is measured.42

Stabilizing the T state with genetic mutations. In order to restore T state stability,
point mutations which have been shown to stabilize the T state in wild type hemoglobin were
incorporated into our mutants. Specifically the 108th residue in the β globin was changed
from asparagine to lysine (also known as the Presbyterian mutation, βN108K) 43-45 and the
96th residue in the α globin was changed from a valine to a tryptophan (αV96W). 44-46 As it
has been shown that these mutations have additive effects43, 44, 47, single and double mutants
of α-cpβ were made to assess the effects of these mutations on the ligand binding behavior of
permuted hemoglobin. Laser flash photolysis experiments were repeated with the new
mutants (see Figure 18). The βN108K mutant showed some minor improvement in
increasing the slow phase of ligand binding. Contrary to expectation, the αV96W mutant
reduced the percent of slow phase binding, suggesting that rather than stabilizing the T state,
it had further destabilized it. The double mutant, showed that the effects of these mutations
are still additive as it has less slow phase binding compared to the βN108K, but more than
19

αV96W.48 X-ray crystallography studies are underway to get atomic level details of the
αV96W mutant structure as a first step in trying to understand why it is deviating from its
expected behavior.

Figure 18: Full Flash Photolysis Results of α-cpβ Containing T State Stabilizing Mutations. The red
line represents HbA, the blue is α-cpβ+ βN108K, the purple line represents αcpβ, the orange line
represents α-cpβ+ αV96W+βN108K and the pink line represents α-cpβ + αV96W.48

ScHb+βN108K: A scHb in which all four subunits are connected via intersubunit
linkers has been isolated. The scHb was designed to serve as a monomer building block for
the assembly of oligomeric hemoglobins. Characterization of ligand binding to scHb using
flash photolysis shows the same results obtained previously with the α-cpβ mutants. The T
state has been significantly destabilized without perturbation of the R state ligand binding
(see Figure 19). Since the incorporation of the Presbyterian mutation (N108K) in α-cpβ
appeared to improve the stability of the T state, the N108K mutation was included in a
20

“second generation” scHb mutant. Characterization of the scHb+N108K hemoglobin has
been hampered by poor expression yields for that mutant.

Figure 19: Full (left panel) and Partial (right panel) Flash Photolysis for scHb compared to HbA, α-cpβ
and sc-α-cpβ.

The initial goal of this project was to introduce T state stabilizing mutation N108K
into scHb and then study its structure and ligand binding however this was hampered due to
low yields so the focus of the project was switched to studying the T state stabilizing
mutations in the higher yielding αcpβ framework. Thus, the current goal of this work is to
crystallize the αcpβ mutants containing single and double T state stabilizing mutations of
V96W and N108K in order to gain an atomic level understanding of the effects of these
mutations on the stability, structure, and function of the permuted Hbs.

21

Materials and Methods
Transformation by electroporation: SOC medium contains 0.5% (w/v) yeast extract,
2% (w/v) Tryptone, 10 mM NaCl, 2.5 mM KCl, 10mM MgCl2, 10 mM MgSO4 and 20 mM
glucose. LB Agar containing 10 g/L of Bacto-tryptone, 5 g/L yeast extract 170 mM NaCl,
pH 7.0, and 15 g/L of Agar. Electrocompetent E.coli BL21 (DE3) cells were thawed on ice
along with a 1 mm gap electroporation cuvette (Fisher Scientific). The plasmid DNA
encoding mutant hemoglobin genes was thawed, thoroughly mixed, and then spun down in a
microcentrifuge. Once thawed, 40 to 50 µL of the electrocompetent cells were transferred
into the cuvette with slow and careful pipetting. 2 µL of the plasmid DNA were added and
mixed gently with the cells by careful pipetting. The mixture was incubated on ice for 10 to
30 minutes. The E.coli cells were transformed via electroporation using a Biorad Gene Pulser
II set to a potential of 1.25 kV/mm, a capacitance of 25 µF and a resistance of 200 ohms.
Immediately after electrical discharge, the cells were bathed in 1 mL of the SOC medium,
which had been warmed to room temperature. The cells were gently transferred to a glass
culture tube and incubated at 37 °C with ~200 rpm shaking for one hour. The culture (20-200
µL) was then spread on LB-agar plates containing 4 µM tetracycline, and incubated at 37 °C
until colonies appeared (approximately 16 hours). One colony was transferred to a culture
flask and incubated in LB with 10 µM tetracycline at 37 °C with shaking at ~200 rpm
overnight (12 to 16 hours). Seed stock was prepared from the overnight culture flask using
0.5 mL of cell culture to 1 mL sterile 40% glycerol then flash frozen in liquid N2 and stored
at -80 °C.
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Protein Expression: One liter of rich medium broth (TB) was prepared by adding 24
g of yeast extract, 12 g of tryptone, 4 mL of glycerol to Fernbach flasks. 100 mL of
potassium phosphate (KPhos) buffer was prepared using 2.31 g of monobasic potassium
phosphate and 16.43 g of dibasic potassium phosphate trihydrate. The TB broth and KPhos
buffers were sterilized in an autoclave. Overnight cell cultures were prepared in 10 mL of
autoclaved LB (10 g/L of Bacto-tryptone, 5 g/L yeast extract and 170 mM NaCl, pH 7.0 )
and 10 µM tetracycline that was inoculated with E.coli seed stock. The inoculated culture
was incubated in shake flasks for 12 to 16 hours at 200 rpm at 37 °C. After which the 10 mL
overnight cultures were added to the 1 L of TB medium in Fernbach flasks along with
100mL of the KPhos buffer and 10 µM tetracycline. The E.coli cells were grown at 37°C at
200 rpm to an OD600 of 1.8-1.9 (approximately 3-4 hours) at which point the temperature was
reduced to 30 °C. When OD600 reached 2.1, the cooler was turned on to obtain a target
temperature of 30°C and protein production was induced with the addition of 1 mM
isopropylthiogalactoside (IPTG). Extracellular hemin solution (.0500 g of hemin dissolved in
5 mL of 20 mM NaOH and then filtered with a sterile 0.2 µm disposable cellulose acetate
membrane syringe filter (VWR International)) was added to each 1 L culture in 1 mL
portions every hour for 4 to 5 hours. At the end of expression stage the cells were harvested
by centrifugation at 5,000 x g for 10 minutes at 4°C. The cell pellets were then transferred to
50 mL Falcon tubes along with 1-2 mL of Lysis Buffer (17 mM NaCl, 50 mM Tris-HCl, pH
8.5) then flash frozen in liquid N2 and stored at -80 °C.
Protein Purification: Cell pellets were thawed in a cold water bath and resuspended
to a total volume of 30 to 35 mL with lysis buffer. The cells were then lysed by sonication on
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ice for 2 x 45 seconds with a 50% duty cycle and power output level 6 using a Branson
Instruments, Inc. Sonifier (model 450) equipped with a 1.8 cm diameter horn. The crude
lysate was clarified by centrifugation at 21000 x g at 4°C for 20 minutes. The pH of the
clarified lysate was adjusted to the range 8-8.5 and Zn(OAc)2 was added to a final
concentration of 2-4 mM. The lysate was re-clarified by centrifugation at 40,000 x g at 4°C
for 20 min. The clarified lysate was further clarified by filtration using a Millipore cassette
with a glass prefilter followed by a 0.45 µM SFCA bottle top vacuum filter (Fisher
Scientific).
Immobilized metal ion affinity chromatography (IMAC): The initial purification step
for mutant hemoglobins was performed using a 10 mL column of Amersham Pharmacia
Biotech Chelating Sepharose Fast Flow resin. The IMAC column was prepared by running 4
column volumes (CV) of 0.2 M NaCl, 2 CV of 20 mM Zn(OAc)2 and 6 CV of 0.2 M NaCl at
4 mL/min. The filtered lysate was then loaded onto the IMAC column. The column was
washed with 8 CV 20 mM Tris-HCl + 0.5 M NaCl pH 8.5; 2 CV of 250 mM Tris-HCl pH 8.5
and 6 CV of 20 mM Tris-HCl, pH 8.5. The protein was then eluted using 20 mM Tris-HCl+
15 mM EDTA pH 8.5 and a reduced flow rate of 3 mL/min. The column was regenerated
using 2 CV of 50 mM EDTA, 2 CV of NaCl and 2 CV of NaOH.
Ion exchange chromatography (IEC): Proteins were further purified by anion
exchange chromatography using an Amersham Biosciences Mono Q 10/100 GL column (8
mL volume) connected to a GE Health Sciences Äktapurifier 900 system. The column was
prepared with 3-4 CV of water followed by 3-4 CV of Buffer A (20 mM Tris-HCl pH 8.5), 34 CV of Buffer B (20 mM Tris-HCl + NaCl pH 8.5) and 3-4 CV of Buffer A. Protein
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samples were prepared for loading by exchanging the IMAC elution buffer with Buffer A
using centrifugation in Amicon Ultra concentrators with a molecular weight cut-off of 10
kDa at 4000 x g for 10 to 12 minutes. Prior to injection, the buffer-exchanged protein
solution was concentrated to a volume of 500 µL and filtered through a 0.22 µM cellulose
acetate Spin-X centrifuge tube filter (Costar). The protein was eluted using a gradient of
increasing Buffer B concentration from 0 to 100% over 20 CVs. The absorbance of the eluent
was monitored at 280 nm and fractions with significant absorbance were collected. Protein
samples generally eluted between 25 and 30 % Buffer B composition. The column was
regenerated with 10 CV of 2 M NaCl followed by 5 CV of 1 M NaOH, 4 CV of H2O, 4 CV
of 2M NaCl, 5 CV of H2O and then prepared for storage with 3 CVs of 20% (v/v) ethanol.
High Pressure Size-Exclusion Chromatography (HPSEC): The final purification step
was performed using an Amersham Pharmacia Biotech Superdex 75 size exclusion column
(24 mL bed volume) connected to an Äkta purifier FPLC system (GE HealthSciences). The
column was prepared with 1-2 CV of water followed by 1-2 CV of 20 mM ammonium
acetate at pH 8.5. Protein was prepared by concentrating to 500 µL and filtered using Spin-X
filters as described above. The absorbance of the eluent was monitored at 280 nm and all
peaks with significant absorbance were collected. The protein samples generally eluted at a
volume of approximately 15 mL. The column was regenerated by the following protocol: 2
CV H2O, 2.5 CV NaOH, 2 CV water and then stored after treatment with 1.5 CV 20% (v/v)
ethanol.
UV-Visible Spectroscopy (UV-Vis): The concentration of hemoglobin samples was
determined using UV-Vis spectroscopy using a Fisher Scientific Nanodrop 1000
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spectrophotometer. The Soret band in the 414-416 nm range for oxy-hemoglobin was used
along with a molar extinction coefficient of 125,000 M-1 cm-1 to calculate sample
concentration.49 The Soret band in the 418-420 nm range for cyanomethemoglobin along
with a molar extinction coefficient of 124,000 M-1 cm-1 to calculate the concentration.50
SDS-PAGE: Protein electrophoresis gels were made with a 10% (w/v) SDS-PAGE
stacking layer and a 15% (w/v) SDS-PAGE resolving layer. Protein samples were prepared
with 10 µL of protein solution (containing at least .01 mg of protein), 5 µL of stain (50mM
Tris-HCl, 2% SDS, 0.2% bromophenol blue, 10% glycerol, pH 6.8), and 1 µL 0.1 M DDT.
The samples were then incubated at 100 °C for approximately 5 minutes. 10 µL of the
protein molecular weight standard ladder (Spectra Multicolor Broad Range Protein Ladder
from Thermo Scientific) was loaded onto the gel. 15 µL of each samples were loaded onto
the gel which was placed in the electrophoresis apparatus with Tris-glycine reservoir buffer
(25mM Tris, 250 mM glycine, 0.1% (w/v) SDS, pH 8.3). The gel was electrophoresed at 65
V for approximately 30 min (until the tracking dye was through the stacking gel) and then at
115 Volts until the tracking dye reached the bottom of the gel. The gel was then stained with
Coomassie Brilliant Blue solution (50% (v/v) methanol, 10% (v/v) acetic acid, 0.1% (w/v)
Coomassie Brilliant Blue R250) overnight. The gel was destained with three washing of a
1:3:4 (v/v) glacial acetic acid: methanol: water solution. The gel was then scanned and
analyzed using Image J software (available from the NIH) to determine purity of protein
samples.
Electrospray Ionization Mass Spectrometry (ESI-MS): The proteins were analyzed
using electrospray ionization mass spectrometry with an Applied Biosystems API 2000
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LC/MS/MS mass spectrometer. Samples were prepared in a 1:1 ratio of acetonitrile to water
at a protein concentration of 10 µM. Samples were injected onto the mass spectrometer using
both direct injection using a syringe pump (where the protein bypasses the LC step) and
liquid chromatography injections. Mass data was analyzed using the software supplied by the
manufacturer.
Cyanomet Conversion: To stabilize the protein during the crystallization process and
prevent it from precipitating the hemoglobin was converted into its cyanomet isoform. This
was achieved by treating the protein with Drabkin’s reagent (10 mM KCN, 7mM K3Fe(CN)6
and 120 mM NaHCO3) in tenfold excess to a final volume of 500 µL then immediately
applied to the HPSEC with 20 mM ammonium acetate at pH 8.5.
Crystal Tray Preparation: The hanging drop method of protein crystallization was
applied in 24-well crystallography trays (VDXm Plate) as follows: the rims of the wells were
coated in white petroleum jelly to prevent dehydration of the experimental solution in the
well. The well held 400 µL of the mother liquor while a 1:1 ratio of mother liquor to protein
was placed on a siliconized glass cover slip which was then inverted and sealed to the
greased crystallization well. Some trials used a 2:1 ratio of mother liquor to protein. The
drops were examined for crystal formation with a compound microscope and recorded with a
digital camera.
Selection and harvesting of crystals for X-ray crystallography: Optically transparent
and isolated crystals were captured with a crystallography loop and quickly transferred to a
cryoprotectant solution identical to the mother liquor with the addition of 10-30% glycerol
and examined for stability. Once cryoprotected the crystals were looped and flash frozen by
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submerging in liquid nitrogen. Crystals were stored in magnetically sealed tubes under liquid
nitrogen until they were to be evaluated by X-ray diffraction.
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Results
scHb+ N108K: In order to restore T state stability the βN108K mutation was
introduced to scHb. However while the N108K mutation stabilizes the T state it destabilizes
the protein overall, leading to very low soluble protein expression. In order to preemptively
address the destabilizing effect of the N108K mutation four stabilizing mutations (4sm) were
included in the scHb sequence: αG15A, βG16A, βH226I and βK82D. These four mutations
have been shown to increase the stability of apohemoglobin and thereby enhance expression
levels.51, 52 However the inclusion of the N108K mutation contributed to a four-fold decrease
in yield when compared to its predecessor scHb (see Table 1). Hemoglobin expression
yields were increased by coexpression of the heme uptake genes cassette (hug) from
Plasiomonas shigellodies.53 Presumably, this promotes transport of heme from the culture
medium into the bacterial cells and thereby increases the amount of intracellular heme during
protein biosynthesis. Expression yields are thought to improve by this method, because
apohemoglobin subunits are stabilized by heme binding. In scHb expression experiments, the
coexpression of the hug cassette improved yields. Thus, the hug cassette was also included in
the scHb+βN108K expression plasmid. Two orientations of hug cassette in reference to the
hemoglobin plasmid were tested to determine if gene orientation affected protein expression
yields. Hug 1 indicates that the hug cassette is oriented in the opposite polarity with respect
to the hemoglobin gene, hug 2 indicates that both the hug cassette and hemoglobin are
oriented in the same direction. In growths carried out with hug 1 there was not a significant
change in yield whereas growths with hug 2 showed a decrease in protein yield when
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compared to yields of scHb+N108K without the hug cassette. Despite these efforts, the
combined yield of scHb+N108K from a six liter growth remained below one milligram.

4sm

Average yield of scHb
(mg protein/L of growth medium)
0.58

Average yield of scHb+N108K
(mg protein/L of growth medium)
0.13

Hug 1

0.88

0.12

Hug 2

-

0.04

Table 1: Crude yield of scHb with N108K mutation. The yield was calculated following the IMAC
purification step

Protein expression and purification: The three mutants of interest: α-cpβ+
βN108K+4sm (N108K), α-cpβ+ αV96W+ 4sm (V96W) and α-cpβ+ αV96W+ βN108K+4sm
(6M) were all expressed in BL21 (DE3) cells where the 4sm stands for the four stabilizing
mutations (αG15A, βG16A, βH226I and βK82D).The proteins were purified to ≥ 95% which
was determined from sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE, see Figure 20). The purification process included three column chromatography
steps: immobilized metal ion affinity (IMAC), ion exchange (IEC) and size exclusion
chromatography (SEC). Yields were determined after each purification step (see Table 2 for
average yields). Purification after IEC saw 82% loss in product from post-IMAC pool while
SEC resulted in a 28% loss in product from the IEC pool.
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Figure 20: Samples from three purification steps analyzed by 10% SDS-PAGE. Post IMAC
purity is 25%. Post IEC purity is approximately 94%. Post SEC purity is approximately
96%.

Post IMAC
(mg)

Post IEC
(mg)

Post SEC
(mg)

V96W

73.6

13.5

10

N108K

74.5

12.6

11.6

6M

59.2

11.8

6

Table 2: Protein yields of V96W, N108K and 6M after each purification step were calculated from
absorbance at 413 nm.
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ESI-MS: Mass spectrometry data was obtained using both direct injection and liquid
chromatography (LC) methods (see Table 3). The best MS results for the 6M mutant were
obtained with the direct injection method (Figure 21). However, subsequent direct injection
attempts with N108K (Figure 22) and V96W (Figure 23) resulted in a broader range in the
mass reconstruction compared to results obtained with the 6M mutant. In addition, the signal
to noise ratio was higher when compared to the 6M results.

Figure 21: ESI-MS of 6M. Top panel is the mass to charge ratios detected by the ESI-MS. Bottom
panel is the mass reconstruction from the ESI-MS data with α globin peak at 15263 amu and the β
globin at 16553 amu.
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Figure 22: Direct Injection ESI-MS of N108K. Top panel is the mass to charge ratios detected by the
ESI-MS. Bottom panel is the mass reconstruction from the ESI-MS data with the α globin peak at
15210 amu and the β globin peak at 16552 amu

Figure 23: Direct Injection ESI-MS of V96W. Top panel is the mass to charge ratios detected by the
ESI-MS. Bottom panel is the mass reconstruction from the ESI-MS data with the α globin peak at
15262 amu and the β globin peak at 16528 amu
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α globin

β globin

α globin

β globin

expected mass

expected mass

observed mass

observed mass

N108K

15172

16546.9

15210.0

16552.0

V96W

15259.5

16533.9

15262.0

16538.0

6M

15259.5

16546.9

15263.0

16553.0

protein

Table 3: Expected and Observed (via ESI-MS) Masses of α and β Globins

Unexpected higher MW contaminants: In some of the SDS-PAGE gels a band
appeared at approximately 32 kDa (see Figure 24) which is the expected mass for either
homo or heterodimers of hemoglobin subunits, suggesting that the α and/or the cpβ globins
were reacting to form covalent crosslinks. These dimer contaminants were more likely to
appear in the N108K mutant compared to the 6M and V96W mutants. During cell lysis, it
seemed that our original sonication protocol was resulting in overheating of the crude lysate
despite being conducted on ice. The intensity of these dimer bands was reduced after the
sonication step was changed from a single ninety second cycle to two forty-five second
cycles.
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32 kDa band

Figure 24: 10% SDS-PAGE Gel. Lane one is the Protein Ladder, lane two is N108K, lane three is 6M
and lane four is V96W.

Crystallization: Initial crystal growth conditions for all mutants were based on the
successful crystallization of α-cpβ, where the conditions ranged from PEG 3350
concentrations of 22 to 24 % (w/w) and a pH of 6.5 to 8.9 (M.Murphy, P.C. Spiegel,
unpublished results54). Initial attempts to crystallize N108K and V96W mutants in their oxy
isoform led to significant protein precipitation. Using lower concentrations of protein did not
reduce precipitation; thus, the proteins were converted to the more stable cyanomet isoform.
Hemoglobin can bind to other ligands such as carbon monoxide and cyanide to form,
respectively, carbonmonoxyhemoglobin and cyanomethemoglobin. Cyanomethemoglobin is
more stable compared to oxy hemoglobin and less likely to precipitate from solution. To
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determine if the ratio of mother liquor to protein had an effect on precipitation or
crystallization two drops of differing ratios (1:1 and 2:1) where placed on the same
coverslips. The 2:1 mother liquor to protein appeared to prevent precipitation, but there was
no improved crystal formation.

Figure 25: Image of stacked 24-well crystallization trays
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Figure 26: General layout of a gradient tray with concentration of PEG 3350 (w/v)
% varying along the horizontal axis and pH varying along the vertical axis

N108K crystals: Small crystals with good morphology formed in conditions of PEG
3350 concentration of 21% and a pH of 6.5. These were irradiated with X-rays; however,
they did not produce a diffraction pattern.

Figure 27: Crystals of N108K
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Crystallization of V96W: Crystals were observed to form in conditions containing
PEG 3350 concentrations ranging from 23 to 25% (w/v) and a pH range of 6.5 to 6.8. These
crystals had a unique morphology as they were spherical. X-ray analysis of these crystals did
not produce any diffraction patterns. Subsequent trays have produced similar crystals which
are smaller in size.

Figure 28: Crystals of V96W

Crystallization of 6M: Crystals were observed to form in conditions of PEG 3350 of
23% (w/v) and a pH of 6.5. The crystals were a similar morphology as the V96W crystals
and did not produce a diffraction pattern.

Figure 29: Crystals of 6M
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Discussion
scHb+N108K: Yields of the scHb+N108K were four times lower than that of scHb.
Low yield of purified protein is a difficulty faced with many of our mutants, especially with
scHb. This is a problem as it takes many growths to produce enough hemoglobin to use in
characterization studies. Additionally, in order to be used as a blood substitute large amounts
of hemoglobin must be produced in a cost effective manner. Lower yields for scHb+N108K
were expected as addition of the N108K mutation destabilizes protein. The N108K mutation
was incorporated because it is known to stabilize the T state.43-45 In order to counteract the
expected reduction in expression yield, four mutations (βG16A, βH226I, αG15A, βK82D)
which are known to stabilize globin chains and thereby increase expression yields of soluble
protein51, 52 were included in our scHb+N108K mutant. Despite the presence of the four
stabilizing mutations protein yield was still low. In previous studies Villarreal et al. found
that globin yields increased when the heme uptake genes from Plesiomonas shigelloides were
incorporated into the hemoglobin expression plasmid. The increased amount of intracellular
heme allows the hemoglobin to fold properly and therefore provides a stabilizing effect.53
Protein yields of scHb+N108K did not improve with this method. In an effort to obtain
sufficient protein to characterize the effect of the N108K mutation we turned to bioreactor
production. Use of a bioreactor allows growth of E.coli cells to a higher cell density which in
turn would increase the hemoglobin yield. Smith et al. have found that producing
recombinant hemoglobin in a bio reactor in combination with the hug cassette, increased
protein yield55. One of our future goals is to use a bioreactor to produce low expressing
recombinant hemoglobins such as scHb+N108K.
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Crystallization: We have not yet isolated crystals that diffract; thus, we do not yet
have X-ray datasets for the Hb mutants used in this work. These proteins in the oxygenbound isoform have shown a propensity to precipitate under crystallization conditions that
have yielded diffraction data for other Hb mutants. In light of this observation, we have
attempted to crystallize the more stable cyanomethemoglobin isoform. Even using the
cyanomethemoglobin isoform the protein tended to precipitate out of solution at low pH (6.0
and 6.5) while at high pH precipitation was not an issue the protein also did not produce
crystals. In all three mutants the pH range in which we saw formation of small crystals was
6.5-7.0 with a PEG 3350 concentration range of 20-25%. Our future goals are to obtain
diffractable crystals by narrowing the optimum conditions and seeding using the smaller
crystals obtained to date.
Structural Studies: The structures of N108K and V96W single and double mutants
are of interest because the permuted hemoglobin containing the V96W mutation shows a
destabilizing effect on the T state, which was unexpected as the V96W mutation in wild-type
hemoglobin appears to stabilize the T state.44-47 The crystal structure of a recombinant
hemoglobin with the V96W mutation in an α-aquomet, β-deoxy T-state contained novel
water mediated hydrogen bonds between V96W and β101E in the T state46 (see Figure 30).
Puius et al. proposed that the T-state stabilizing effect of the V96W mutation was due to
these water mediated hydrogen bonds. In the crystal structure of a recombinant hemoglobin
containing the V96W mutation in a carbonmonoxy R state they found an interaction between
β101E and β104R, which is usually only found in the T state (see Figure 31).46 If these
interactions have been altered due to circular permutation it could be a possible explanation
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for the loss of stabilizing effects of V96W on the T state. The V96W stabilizing bonds occur
over the α1β2 interface and are in close proximity to the linker added between the native β
globin termini as part of the circular permutation process (Figure 32). Additionally the
residues involved with the T state stabilization on the β2 globin are located near the Nterminus of the G helix. The C-terminus of the G helix is the site of the new C- terminus in
our circularly permuted β globins (Figure 32). It is possible that the interactions of V96W
which contribute to the stabilization of the T state have been altered due to the circular
permutation in our mutants. The crystal structure of α-cpβ (Michael Murphy, thesis54)
showed that though the circular permutation did not significantly perturb the tertiary structure
it did interfere with some of the T state stabilizing interaction on the interface.

Figure 30: Local hydrogen-bonding network in the T-state structure of rHb (αV96W).46
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Figure 31: Possible interactions of rHb (αV96W) in the R state.46

6
Figure 32: Pymol image showing the proximity of the αV96 (yellow), residues involved in the
stabilization of the T state for the V96W mutation (green) and the circular permuted β globin linker
(cyan and magenta) using αcpβ crystal strucuture

Conclusion: While scHb is a promising scaffold in the development of the next
generation of HBOCs two things need to be accomplished: 1) restoration of T state stability
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via mutations and 2) production of proteins with high expression yield. Mixed results have
been achieved with respect to restoring the T state stability. The permutants containing the
N108K mutation seem to have slightly improved ligand binding kinetics. On the other hand,
mutations on the α1β2 interface such as V96W have a negative effect on restoring T state
stability (but seem to not have any negative effect on the protein yield). Progress toward
understanding these effects on a structural level has been made by narrowing the conditions
under which these mutants can be crystallized. Increasing the yields of the proteins of interest
is an ongoing effort. Incorporation of point mutations known to increase the hemoglobin
stability and coexpression of the hug cassette have led to increases in yields of scHb.
However the introduction of the T state stabilizing mutation N108K has a negative effect on
the yield and an alternate means to combat this destabilization needs to be found. The goals
are:
1) to continue with the crystallization of our single and double mutants containing
V96W and N108K, to allow collection of high quality diffraction data. This is the basis for
developing an atomic-level understanding of the effects of these mutations within the
framework of circular permutation.
2) to develop a bioreactor method which increases the yield of our hemoglobin
mutants in order to obtain sufficient protein for structural and characterization studies of low
yielding mutants such as scHb+N108K.
While the low yields obtained by these mutants make them poor candidates for
clinical use, structural studies of the mutants will improve our ability to predict the effects of
other point mutations on the function of permuted human hemoglobins.
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